- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00045721
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
Phase I Trial of GLIADEL and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug.
PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine implants in treating children who have recurrent malignant glioma.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
- Determine the dose of O(6)-benzylguanine that reliably inhibits alkylguanine-DNA alkyltransferase activity in pediatric patients with recurrent malignant glioma.
- Describe the toxic effects of O(6)-benzylguanine with carmustine implant (Gliadel) in these patients.
- Investigate antitumor response in patients treated with this regimen.
- Characterize the pharmacokinetics of O(6)-benzylguanine when administered continuously over a 9-day period.
OUTLINE: This is a multicenter, dose-escalation study of O(6)-benzylguanine.
Patients receive O(6)-benzylguanine (O6-BG) IV over 1 hour immediately followed by O6-BG IV continuously for 9 days. Two days after initiation of continuous infusion of O6-BG, patients undergo maximal tumor debulking. At the time of surgery, patients receive up to 8 polifeprosan 20 wafers with carmustine (Gliadel) implanted into the resection cavity.
Cohorts of up to 14 patients receive escalating doses of continuous infusion O6-BG until the optimally biologically effective dose (BED) is determined. The BED is defined as the dose at which at least 11 of 14 patients meet the target of complete suppression of alkylguanine-DNA alkyltransferase levels.
Patients are followed at day 11, at weeks 2, 4, 6, 8, and 12, at months 6, 9, and 12, every 6 months for 4 years, and then annually for 5 years.
PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study within 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143-0372
- UCSF Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105-2794
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030-2399
- Texas Children's Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed progressive supratentorial anaplastic astrocytoma or glioblastoma multiforme
- No multifocal disease or leptomeningeal dissemination of tumor
- No evidence of tumor crossing midline
- Limited intraventricular involvement
- Measurable unilateral mass at least 10 mm by contrast-enhanced MRI
- Received prior involved-field radiotherapy as a component of prior therapy
- Amenable to and in need of significant debulking
PATIENT CHARACTERISTICS:
Age
- 3 to 21
Performance status
- Karnofsky 60-100% OR
- Lansky 60-100%
Life expectancy
- More than 8 weeks
Hematopoietic
- Absolute neutrophil count greater than 1,000/mm3*
- Platelet count greater than 100,000/mm3*
- Hemoglobin greater than 8 g/dL (transfusions allowed) NOTE: * Transfusion independent
Hepatic
- Bilirubin no greater than 1.5 times normal
- AST and ALT less than 3 times normal
- Albumin at least 2 g/dL
- No overt hepatic disease
Renal
- Creatinine clearance no greater than 1.5 times normal OR
- Glomerular filtration rate greater than 70 mL/min
- No overt renal disease
Cardiovascular
- No overt cardiac disease
Pulmonary
- No overt pulmonary disease
Other
- Neurological deficits must be stable for at least the past week
- No uncontrolled infection
- No known hypersensitivity to nitrosoureas or polyethylene glycol
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 6 months since prior bone marrow transplantation
- More than 2 weeks since prior colony-stimulating growth factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa)
Chemotherapy
- No more than 2 prior cytotoxic chemotherapy regimens
- No more than 3 prior chemotherapy regimens total
- More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
- Prior systemic carmustine (or other nitrosourea) allowed provided patient did not experience non-hematopoietic grade III/IV toxicity
Endocrine therapy
- Concurrent dexamethasone allowed if on a stable dose for at least the past week
Radiotherapy
- See Disease Characteristics
- At least 3 months since prior radiotherapy
- No prior craniospinal irradiation for metastatic disease
Surgery
- See Disease Characteristics
- Prior biopsy or cytoreductive surgery allowed
Other
- Concurrent anticonvulsants allowed
- No other concurrent anticancer or investigational drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Biologically effective dose of O(6)-benzylguanine administered continuously in pediatric patients with recurrent malignant glioma
|
Toxicities associated with the administration of O(6)-benzylguanine and carmustine implants.
|
Secondary Outcome Measures
Outcome Measure |
---|
Tumor response
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Carmustine
- O(6)-benzylguanine
Other Study ID Numbers
- CDR0000257268
- PBTC-009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on adjuvant therapy
-
Tao OUYANGActive, not recruiting
-
The Central and Eastern European Gynecologic Oncology...RecruitingCervical CancerCzechia
-
PT. Prodia Stem Cell IndonesiaRecruitingNasopharyngeal CancerIndonesia
-
Asan Medical CenterUnknown
-
Medical Research CouncilCompletedHead and Neck Cancer | Non-melanomatous Skin CancerUnited Kingdom
-
Far Eastern Memorial HospitalCompletedHigh-risk Endometrial CancerTaiwan
-
European Organisation for Research and Treatment...UnknownBrain and Central Nervous System TumorsSwitzerland
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Genzyme, a Sanofi CompanyCompleted
-
Center of Personalized Medicine, PirogovaI.M. Sechenov First Moscow State Medical University; Center for New Medical...UnknownBreast Cancer-specific SurvivalRussian Federation